Skip To Main Content
Conor Murray on Muck Rack

Conor Murray

Verified
  • Explainers and Trends Reporter, Forbes
Jersey City
As seen in: Forbes, MSN, MSN Ireland, MSN Money Canada, MSN UK, Yahoo Entertainment, Nature, Wiley Online Library, Yahoo Canada, Yahoo News, Yahoo News Australia and
reporter @forbes / cmurray@forbes.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Conor

Contact Conor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trump Won’t Intervene In Andrew Tate Extradition Process, Leavitt Says Original

|
By Conor Murray Verified
| Forbes Verified
Topline The White House won’t intervene in the extradition process for controversial “manosphere” influencer Andrew Tate, press secretary Karoline Leavitt said Thursday, as Tate claims he is being held in the “highest level of security which exists” as British authorities seek to extradite him and his brother Tristan on dozens of new charges. Andrew Tate and his brother Tristan were arrested in Miami over the weekend.
Open in Who Shared View Duplicates (5) Issue with article?

Eli Lilly solicitará la aprobación de Retatrutida, ya que un estudio muestra una pérdida de peso promedio de 25 kilos

|
By Conor Murray Verified
| Forbes México Verified
Eli Lilly, el fabricante de GLP-1 responsable de Mounjaro y Zepbound, anunció que solicitará la aprobación de la Administración de Alimentos y Medicamentos (FDA) para su potente fármaco para bajar de peso, retatrutida, después de que los estudios demostraran que los participantes perdieron un promedio de casi 25 kilos tras 80 semanas de tratamiento.
Open in Who Shared Issue with article?

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds Original

|
By Conor Murray Verified
| Forbes Verified
Topline Eli Lilly, the GLP-1 maker behind Mounjaro and Zepbound, said it would file for Food and Drug Administration approval of its powerful retatrutide weight-loss drug after studies found participants lost an average of nearly 56 pounds after 80 weeks on the medication. Eli Lilly says it plans to file for regulatory approval for retatrutide.
Open in Who Shared View Duplicates (3) Issue with article?
See all 4,595 licensed articles (4,661 Total)